Skip to main content

Table 4 Comparative estimates of costs, QALYs, and ICERs: basecase analysis

From: Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates

 

Anti-TNF user

Anti-TNF non-user

Increment (user vs non-user)

95% CIa

Canada

 Costs

15,741

1703

14,038

(12,179, 15,991)

 QALYs

0.626

0.609

0.017

(−0.008, 0.042)

 ICER

  

818,186

(330,082, Dominated)

France

 Costs

15,773

1763

14,010

(12,423, 15,694)

 QALYs

0.620

0.607

0.013

(−0.011, 0.036)

 ICER

  

1,105,859

(375,227, Dominated)

UK

 Costs

16,952

756

16,195

(13,327, 19,181)

 QALYs

0.627

0.606

0.021

(−0.015, 0.059)

 ICER

  

766,217

(264,164, Dominated)

Germany

 Costs

15,617

1874

13,743

(11,848, 15,759)

 QALYs

0.642

0.617

0.025

(0.001, 0.050)

 ICER

  

545,808

(272,286, 18,727,278)

Hong Kong 

 Costs

15,764

722

15,042

(11,825, 18,898)

 QALYs

0.619

0.586

0.033

(−0.011, 0.076)

 ICER

  

456,850

(189,636, Dominated)

  1. aLower bound = 2.5th, upper bound = 97.5th percentile of bootstrapped distribution